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Abstract
Objectives
To identify the reasons patients miss taking their antiretroviral therapy (ART) and the proportion who miss their ART because of symptoms; and to explore the association between
symptoms and incomplete adherence.

Methods
Secondary analysis of data collected during a cross-sectional study that examined ART
adherence among adults from 18 purposefully selected sites in Tanzania, Uganda, and
Zambia. We interviewed 250 systematically selected patients per facility (18 years) on
reasons for missing ART and symptoms they had experienced (using the HIV Symptom
Index). We abstracted clinical data from the patients’ medical, pharmacy, and laboratory
records. Incomplete adherence was defined as having missed ART for at least 48 consecutive hours during the past 3 months.

Results
Twenty-nine percent of participants reported at least one reason for having ever missed
ART (1278/4425). The most frequent reason was simply forgetting (681/1278 or 53%), followed by ART-related hunger or not having enough food (30%), and symptoms (12%). The
median number of symptoms reported by participants was 4 (IQR: 2–7). Every additional

PLOS ONE | DOI:10.1371/journal.pone.0147309 January 20, 2016

1 / 15

Reasons for Missing Antiretroviral Therapy

and Prevention (CDC) and the Health Resources&
Services Administration (HRSA) under the terms of
the contract no. 2006-N-08428 with FHI 360. The
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data collection, data analysis, data interpretation, and
writing of the manuscript.

symptom increased the odds of incomplete adherence by 12% (OR: 1.1, 95% CI: 1.1–1.2).
Female participants and participants initiated on a regimen containing stavudine were more
likely to report greater numbers of symptoms.

Competing Interests: The authors have declared
that no competing interests exist.

Symptoms were a common reason for missing ART, together with simply forgetting and
food insecurity. A combination of ART regimens with fewer side effects, use of mobile
phone text message reminders, and integration of food supplementation and livelihood programmes into HIV programmes, have the potential to decrease missed ART and hence to
improve adherence and the outcomes of ART programmes.

Conclusions

Introduction
At the end of 2013 two-thirds of the estimated 35 million people globally living with HIV lived
in sub-Saharan Africa.[1] The number of people receiving antiretroviral treatment (ART)
reached about 13 million. Sub-Saharan Africa achieved the greatest increase in ART coverage
by reaching 9 million people, corresponding to about 37% coverage among people living with
HIV in that region.[1,2] The goal of ART is to achieve and sustain viral suppression to achieve
the full clinical and prevention benefits of HIV treatment.[3,4] A systematic review of studies
from low-and middle income countries reported a pooled estimate of viral suppression (<1000
copies/ml) of 78% (95% confidence interval (95% CI):68%-86%) at 12 months after ART initiation.[5]
Achieving viral suppression requires consistent adherence to ART.[6] Factors identified in
the literature as affecting ART adherence include patient characteristics (socio-demographic
and psychosocial factors), patient/provider aspects (patient-provider interactions, trust, and
confidentiality), health-system related factors (waiting time at the clinic, transport), disease
characteristics (HIV-related symptoms), and therapy-related factors (number of pills, medication side effects).[7,8]
In order to develop effective adherence interventions, it is important to identify the common reasons people report for not taking their ART. We used data collected during a cross-sectional study conducted in 2011 that examined adherence to ART among adults in three
countries in sub-Saharan Africa: Tanzania, Uganda, and Zambia.[9] In the primary paper we
examined individual and programmatic factors associated with incomplete adherence. We
found that 3% of participants missed two or more consecutive days of their ART in the past
three months, and that having greater versus less self-reported HIV-related symptoms (a
dichotomized variable based on the country-specific median number of symptoms) was significantly associated with incomplete adherence. In this secondary analysis we focused on selfreported reasons for ever missing ART and investigated the role of symptoms in missing ART.
We also explored the association between having experienced specific symptoms and incomplete adherence.

Methods
Design and study setting
From May to October 2011, a cross-sectional study was conducted among ART patients from
18 purposively selected study sites in Tanzania, Uganda, and Zambia. Site selection has been
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described in an earlier publication [10] and included clinics from different levels in the health
system (ranging from rural health centres to referral hospitals), from different types of health
facilities (public sector, non-governmental organizations (NGOs), or faith-based organizations), and with different ART provision experiences and adherence strategies.

Inclusion criteria
Patients attending the study sites who were at least 18 years of age at ART initiation, who initiated ART at least six months prior to the interview, and who spoke one of the study languages
were eligible for inclusion.

Data collection and sampling
Based on clinic client flow, participants were selected using a systematic sampling approach
with every fifth patient selected at the larger facilities and every third patient at the smaller clinics. After selection, potential participants were screened for eligibility by trained research interviewers, and, if they consented, interviewed until we obtained a sample of 250 eligible patients
from each facility (4500 patients in total).

Measures
The survey was designed in English and then translated into 10 languages (Swahili for Tanzania; Acholi, Luganda, Lumasaaba, Lunyankore for Uganda; and Bemba, Chewa, Lozi, Nyanja
and Tonga for Zambia) and pretested during the training of the fieldworkers and piloting of
the study-instruments.
The survey contained several measures on self-reported adherence, and questions on psychosocial factors including stigma (Internalized Stigma Scale [11]), depression (Hopkins
Symptoms Checklist [12]), social support (Duke University Functional Social Support questionnaire [13]), and alcohol abuse (CAGE [14]).
The survey also included a list of 16 reasons for ever missing ART (based on the AACTG
questionnaire) [15] and on symptoms experienced in the four weeks prior to the interview.
Symptoms were collected using a modified HIV Symptom Index that has 20 items scored on a
five point Likert scale.[16] During translation and pre-testing the team modified the responses
from a five point to a four point Likert scale, with 0 representing the absence of that symptom
and 3 indicating that the patient did have the symptom and it bothered them “a lot” resulting
in an index that ranges from 0 to 60. The participant was also asked if they attributed the symptom to their ART.
Based on previous evidence of the importance of treatment interruptions as a predictor of
viral load failure and resistance [17,18], and because missing ART for at least 48 consecutive
hours was the strongest measure related to virological failure during our primary analysis, we
constructed a missed at least 48 consecutive hours measure from two questions about missed
tablets in the past 3 months to define incomplete adherence.[9]
Data regarding ART initiation (ART start dates and regimens, and pre-ART characteristics)
were abstracted from the patient’s medical, pharmacy, and laboratory records using structured
data abstraction forms.

Data management and analysis
All data were double entered in a study database using EpiData Entry 3.1 (EpiData Association,
Odense, Denmark) at the in-country research organizations, and then transferred to the central
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data office at Family Health International 360 (FHI 360) for further cleaning and consistency
checks.
For data analysis, the proportions of reasons for ever missing one’s ART and experiences of
symptoms in the past four weeks are reported. Because of the dependency on self-reported
symptoms, we investigated the relationship between symptoms and incomplete adherence in
the past three months as a purely explorative objective, and therefore limited this analysis to
univariate analysis only. We also explored the association between specific antiretroviral drugs
(nevirapine versus efavirenz, and stavudine versus zidovudine) and symptom burden
(expressed as the HIV Symptom Index score) using multiple linear regression, with backwards
stepwise elimination, including site as a fixed effect. Variables associated with symptom burden
with a p-value <0.10 were considered for multivariable analysis, and variables with a p-value
<0.05 in the multivariable analysis were considered significant.

Ethics statement
The study was reviewed and approved by the institutional review board (IRB) of the U.S. Centers for Disease Control and Prevention (CDC) and the six partner and national ethical review
committees. The Partners Healthcare IRB ceded review to FHI 360.

Results
A total of 6825 patients were screened for eligibility at the participating sites. Of these 1848
patients were ineligible, and 482 did not provide informed consent. An additional 70 patients
with no data on missed ART for at least 48 consecutive hours were excluded, leaving 4425
patients for the final analysis.

Characteristics of study population
Characteristics at the time of the interview and at ART initiation, stratified by country, are presented in Table 1. Participants were predominantly female (68%) and had started ART between
2002 and 2011. At ART initiation the median age was 40 years (inter quartile range (IQR):
34–47 years) and the median CD4 cell count was 145 cells/μl (IQR: 75–217). At the time of the
interview, the median time on ART was 4 years (IQR: 2–5 years) and about 45% of participants
had changed their ART regimen since initiation. Twenty-three percent changed from an initial
stavudine (d4T) containing regimen, 13% from an initial nevirapine (NVP) containing regimen and 7% from an initial efavirenz (EFV) containing regimen. One-third of patients (32%)
were receiving AZT/3TC/NVP, 17% AZT/3TC/EFV, and 16% d4T/3TC/NVP or TDF/
3TC-FTC/EFV at the time of data collection. About 3% of patients were receiving a secondline regimen that contained a protease inhibitor.

Incomplete adherence (defined as missed ART for at least 48
consecutive hours during the past 3 months)
About 3% (141/4425) of our study participants had missed taking their ART for at least 48 consecutive hours during the past 3 months.

Reasons for ever missing one’s ART
Among all ART patients, 29% of participants reported at least one reason for having ever
missed ART (1278/4425), with only 0.2% (9/4425) missing responses to these questions. About
half of patients who reported ever missing ART (53% or 681/1278) reported they simply forgot,
followed by having too much hunger because of ART or not having enough food (30%), and
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Table 1. Characteristics at interview and at ART initiation of study population in multi-country (Tanzania, Uganda, and Zambia) adherence study,
2011.
Characteristic

Tanzania (n = 1469)

Uganda (n = 1474)

Zambia (n = 1482)

Total number of patients (n = 4425)

Gender: n (%)
Male
Female

394 (26.8)

505 (34.3)

520 (35.1)

1419 (32.1)

1075 (73.2)

969 (65.7)

962 (64.9)

3006 (67.9)

At interview
Age (years): median (IQR)

41 (35–47)

39 (34–46)

40 (34–47)

40 (34–47)

Years on ART: median (IQR)

3.2 (2.0–4.6)

3.6 (2.2–5.4)

4.2 (2.5–5.7)

3.6 (2.2–5.3)

CD4 (cells/μL): median (IQR)

372 (243–548)

368 (245–524)

427 (291–588)

391 (255–560)

701 (47.7)

803 (54.5)

700 (47.2)

2204 (49.8)

Missing: n (%)
ART regimen: n (%)
d4T-3TC-NVP

549 (37.4)

11 (0.7)

158 (10.7)

718 (16.2)

AZT-3TC-EFV

389 (26.5)

296 (20.1)

76 (5.1)

761 (17.2)

AZT-3TC-NVP

258 (17.6)

898 (60.9)

253 (17.1)

1409 (31.8)

114 (7.8)

83 (5.6)

493 (33.3)

690 (15.6)

PI-containing

31 (2.1)

39 (2.6)

66 (4.5)

136 (3.1)

Other

38 (2.6)

134 (9.1)

369 (24.9)

541 (12.2)

Missing

90 (6.1)

13 (0.9)

67 (4.5)

170 (3.8)

TDF-3TC/FTC-EFV

Regimen containing: n (%)
EFV

517 (35.2)

382 (25.9)

641 (43.3)

1540 (34.8)

NVP

823 (56.0)

1036 (70.3)

708 (47.8)

2567 (58.0)

d4T

575 (39.1)

23 (1.6)

207 (14.0)

805 (18.2)

AZT

660 (44.9)

1217 (82.6)

347 (23.4)

2224 (50.3)

TDF

123 (8.4)

221 (15.0)

787 (53.1)

1131 (25.6)

Yes

663 (45.1)

667 (45.3)

670 (45.2)

2000 (45.2)

No

806 (54.9)

807 (54.7)

812 (54.8)

2425 (54.8)

Regimen change since ART initiation: n (%)

Change from NVP at initiation: n (%)
Yes

246 (16.7)

141 (9.6)

197 (13.3)

584 (13.2)

No

708 (48.2)

924 (62.7)

504 (34.0)

2136 (48.3)

Not applicable

515 (35.1)

409 (27.7)

781 (52.7)

1705 (38.5)

Yes

165 (11.2)

59 (4.0)

64 (4.3)

288 (6.5)

No

342 (23.3)

259 (17.6)

495 (33.4)

1096 (24.8)

Not applicable

962 (65.5)

1156 (78.4)

923 (62.3)

3041 (68.7)

Yes

345 (23.5)

400 (27.1)

256 (17.3)

1001 (22.6)

No

442 (30.1)

6 (0.4)

183 (12.3)

631 (14.3)

Not applicable

682 (46.4)

1068 (72.5)

1043 (70.4)

2793 (63.1)

212 (14.4)

82 (5.6)

110 (7.4)

404 (9.1)

Change from EFV at initiation: n (%)

Change from d4T at initiation: n (%)

Change from AZT at initiation: n (%)
Yes
No

427 (29.1)

840 (57.0)

256 (17.3)

1523 (34.4)

Not applicable

830 (56.5)

552 (37.4)

1116 (75.3)

2498 (56.5)

At ART initiation
Year of ART initiation: n (%)
2002–2004

10 (0.7)

60 (4.1)

97 (6.5)

167 (3.8)

2005

123 (8.4)

180 (12.2)

192 (13.0)

495 (11.2)

2006

155 (10.6)

152 (10.3)

209 (14.1)

516 (11.7)
(Continued)
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Table 1. (Continued)
Characteristic

Tanzania (n = 1469)

Uganda (n = 1474)

Zambia (n = 1482)

Total number of patients (n = 4425)

2007

198 (13.5)

224 (15.2)

254 (17.1)

676 (15.3)

2008

272 (18.5)

219 (14.9)

241 (16.3)

732 (16.5)

2009

315 (21.4)

280 (19.0)

235 (15.9)

830 (18.8)

2010

356 (24.2)

313 (21.2)

240 (16.2)

909 (20.5)

2011

36 (2.5)

43 (2.9)

11 (0.7)

90 (2.0)

4 (0.2)

3 (0.2)

3 (0.2)

10 (0.2)

Missing
WHO clinical stage: n (%)
Stage 1 and 2

414 (28.2)

704 (47.8)

567 (38.3)

1685 (38.1)

Stage 3

659 (44.9)

512 (34.7)

671 (45.3)

1842 (41.6)

Stage 4

274 (18.6)

151 (10.2)

92 (6.2)

517 (11.7)

Missing

122 (8.3)

107 (7.3)

152 (10.2)

381 (8.6)

138 (68–218)

149 (83–211)

147 (75–228)

145 (75–217)

281 (19.3)

296 (20.1)

312 (21.1)

889 (20.1)

d4T-3TC-NVP

736 (50.1)

394 (26.7)

396 (26.7)

1526 (34.5)

AZT-3TC-EFV

421 (28.7)

251 (17.0)

77 (5.2)

749 (16.9)

AZT-3TC-NVP

218 (14.8)

668 (45.3)

288 (19.5)

1174 (26.5)

36 (2.5)

54 (3.7)

403 (27.2)

493 (11.1)

CD4 (cells/μL): median (IQR)
Missing: n (%)
ART regimen: n (%)

TDF-3TC/FTC-EFV
PI-containing
Other
Missing

5 (0.3)

16 (1.1)

12 (0.8)

33 (0.8)

51 (3.5)

13 (0.9)

95 (6.4)

159 (3.6)

2 (0.1)

78 (5.3)

211 (14.2)

291 (6.6)

Regimen containing: n (%)
EFV

507 (34.5)

318 (21.6)

559 (37.7)

1384 (31.3)

NVP

954 (64.9)

1065 (72.3)

701 (47.3)

2720 (61.5)

d4T

787 (53.6)

406 (27.5)

439 (29.6)

1632 (36.9)

AZT

639 (43.5)

922 (62.6)

366 (24.7)

1927 (43.6)

TDF

36 (2.5)

63 (4.3)

409 (27.6)

508 (11.5)

d4T: stavudine; 3TC: lamivudine; NVP: nevirapine; EFV: efavirenz; AZT: zidovudine; TDF: tenofovir; FTC: emtricitabine; PI: protease inhibitor.
doi:10.1371/journal.pone.0147309.t001

feeling sick or uncomfortable because of the ART (12%) (Fig 1). Other frequently cited reasons
included no transport to the pharmacy (11%) and being away from home (3%).
A small number of patients (about 2% of those who ever missed ART or less than 1% of all
patients in the study) have ever missed taking their ART because they were told to stop taking
the drugs by a traditional healer. Of the 4,425 patients in this study, 257 (6%) ever consulted a
traditional healer or herbalist because of HIV, the majority of whom were from Tanzania
(76%).

HIV Symptom Index Score (symptom burden)
Eighty-eight percent of participants reported experiencing at least one symptom during the
past four weeks (Table 2), with responses missing for only a small proportion of participants
(5/4425). The median number of symptoms reported was 4 (IQR: 2–7) with a median HIV
Symptom Index score of 8 (IQR: 3–14). Women reported significantly more symptoms
(median of 4 among women versus 3 among men) and a higher symptom burden (median
HIV Symptom Index score of 8 among women versus 7 among men). More symptoms [5
(IQR: 3–8)] and a higher median HIV Symptom Index score [11 (IQR: 5–17)] were reported in
Uganda (Kruskal Wallis p-value<0.001 for both comparisons).

PLOS ONE | DOI:10.1371/journal.pone.0147309 January 20, 2016

6 / 15

Reasons for Missing Antiretroviral Therapy

Female gender and being initiated on a d4T—or NVP—containing ART regimens were
associated with having more symptoms during univariate analysis (Table 3). During multivariable analysis, females (coefficient: +1.6, 95%CI: +1.0, +2.2) and participants taking ART regimens containing d4T at initiation (coefficient: +0.9, 95% CI: +0.3, +1.4) remained significantly
associated with a greater symptom burden.

Types of symptoms
Fatigue or loss of energy was the most cited symptom (37%), followed by pain, numbness, or
tingling in the hands or feet (35%), and headache (34%). Feeling sad, down, or depressed was
reported by 30% of participants (Table 2). Of these most frequently reported symptoms, only
pain, numbness, or tingling in the hands or feet was attributed to ART by a substantial proportion of participants with this symptom (33%). Other symptoms that were not as common but
more frequently attributed to ART by at least 30% of participants with that symptom included
trouble remembering (37%), hair loss or changes in hair (35%), nausea or vomiting (34%),
problems with having sex (31%), and skin problems (30%).
Men reported significantly more diarrhoea, skin problems, and problems with having sex
while women reported significantly more fatigue or loss of energy; headache; loss of appetite or
change in the taste of food; fever, chills, or sweats; feeling dizzy or lightheaded; troubles
remembering; nausea or vomiting; feeling sad, down, or depressed; weight loss or wasting; hair
loss or hair change; bloating, pain, or gas; and muscle aches or joint pains (data not shown).

Association between symptoms and incomplete adherence
Every additional symptom increased the odds of incomplete adherence by 10% (odds ratio
(OR): 1.10, 95% CI: 1.05–1.15) (data not shown). Patients who reported at least one symptom

Fig 1. Reasons for patients who ever missed ART in multi-country (Tanzania, Uganda, and Zambia)
adherence study (N = 1278), 2011.
doi:10.1371/journal.pone.0147309.g001
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Table 2. Reported symptoms in the past four weeks in multi-country (Tanzania, Uganda, and Zambia) adherence study, 2011.
Tanzania
(n = 1469)
Reporting at least one symptom, n
(%)
Number of symptoms reported,
median (IQR)
HIV Symptom Index score, median
(IQR)

Uganda
(n = 1474)

Zambia
(n = 1482)

Total
(n = 4425)

1193 (81.2)

1389 (94.2)

1325 (89.4)

3907 (88.3)

3 (1–6)

5 (3–8)

4 (2–6)

4 (2–7)

6 (2–12)

11 (5–17)

7 (3–13)

8 (3–14)

Attributed to ARVs
by patient (n, %)

Severe symptoms (“It
bothers me a lot”) (n, %)

Symptom, n (%)
Fatigue or loss of energy

360 (24.5)

754 (51.2)

514 (34.7)

1628 (36.8)

308 (18.9)

534 (32.8)

Pain, numbness, or tingling in the
hands or feet

462 (31.4)

662 (44.9)

436 (29.4)

1560 (35.3)

512 (32.8)

583 (37.4)

Headache

394 (26.8)

610 (41.4)

515 (34.8)

1519 (34.3)

233 (15.3)

415 (27.3)

Felt sad, down or depressed

451 (30.7)

518 (35.1)

340 (22.9)

1309 (29.6)

140 (10.7)

467 (35.7)

Muscle aches or joint pains

382 (26.0)

524 (35.5)

284 (19.2)

1190 (26.9)

314 (26.4)

435 (36.6)

Fat deposits or weight gain

378 (25.7)

289 (19.6)

480 (32.4)

1147 (25.9)

326 (28.4)

145 (12.6)

Fevers, chills, or sweats

237 (16.1)

524 (35.5)

374 (25.2)

1135 (25.6)

178 (15.7)

333 (29.3)

Trouble remembering

220 (15.0)

470 (31.9)

419 (28.3)

1109 (25.1)

405 (36.5)

400 (36.1)

Cough or breathing difﬁculties

208 (14.2)

488 (33.1)

330 (22.3)

1026 (23.2)

128 (12.5)

326 (31.8)

Problems with having sex (such as
loss of interest or a lack of
satisfaction)

316 (21.5)

388 (26.3)

312 (21.1)

1016 (23.0)

317 (31.2)

423 (41.6)

Weight loss or wasting

278 (18.9)

411 (27.9)

321 (21.7)

1010 (22.8)

167 (16.5)

267 (26.4)

Dizzy or lightheaded

250 (17.0)

429 (29.1)

320 (21.6)

999 (22.6)

287 (28.7)

267 (26.7)

Loss of appetite or change in taste
of food

267 (18.2)

341 (23.1)

307 (20.7)

915 (20.7)

252 (27.5)

318 (34.8)

Skin problems (rash, dryness, or
itching)

257 (17.5)

381 (25.8)

205 (13.8)

843 (19.1)

255 (30.2)

369 (43.8)

Difﬁculty falling or staying asleep

259 (17.6)

327 (22.2)

251 (16.9)

837 (18.9)

204 (24.4)

306 (36.6)

Felt nervous or anxious

248 (16.9)

373 (25.3)

191 (12.9)

812 (18.4)

117 (14.4)

271 (33.4)

Bloating, stomach pain, or gas

249 (17.0)

353 (23.9)

194 (13.1)

796 (18.0)

219 (27.5)

265 (33.3)

132 (9.0)

203 (13.8)

189 (12.8)

524 (11.8)

176 (33.6)

147 (28.1)

148 (10.1)

146 (9.9)

181 (12.2)

475 (10.7)

100 (21.1)

122 (25.7)

36 (2.5)

101 (6.9)

42 (2.8)

179 (4.0)

63 (35.2)

60 (33.5)

Nausea or vomiting
Diarrhea or loose bowl movements
Hair loss or hair change
doi:10.1371/journal.pone.0147309.t002

were more likely to have incomplete adherence (OR: 3.0, 95% CI: 1.2–7.4) (Table 4). About
half of the symptoms from the HIV Symptom Index Score (9/20) were associated with incomplete adherence: fatigue or loss of energy (OR: 1.5, 95% CI: 1.0–2.1), fevers, chills, or sweats
(OR: 1.7, 95% CI: 1.2–2.4), nausea or vomiting (OR: 1.7, 95% CI: 1.1–2.7), diarrhoea or loose
bowl movements (OR: 2.2, 95% CI: 1.5–3.4), feeling sad, down, or depressed (OR: 1.5, 95% CI:
1.1–2.1), skin problems (OR: 2.0, 95% CI: 1.4–2.8), cough or breathing difficulties (OR: 1.8,
95% CI: 1.3–2.6), loss of appetite or change in the taste of food (OR: 2.1, 95% CI: 1.4–3.0), and
abdominal pains (OR: 1.6, 95% CI: 1.1–2.3).
Patients who reported feeling sick and uncomfortable because of ART were also more likely
to have incomplete adherence (OR: 3.7, 95% CI: 2.1–6.6).

Discussion
This is the first study to our knowledge to interview more than 4000 patients on their reasons
for ever missing ART and their current experiences with HIV-related symptoms using a
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Table 3. Regression coefficients of factors associated with symptom burden (expressed as HIV Symptom Index Score) in multi-country (Tanzania,
Uganda, and Zambia) adherence study, 2011.
Risk factor

Single regression*

Male (versus female)

Multiple regression*

Coefﬁcient (95% CI)

P-value

Coefﬁcient (95% CI)

P-value

-1.6 (-2.2, -1.0)

<0.001

-1.6 (-2.2, -1.0)

<0.001

+0.9 (+0.3, +1.4)

0.004

WHO clinical stage at ART initiation (versus WHO stage 1 and 2)

0.138

Stage 3

+0.7 (+0.1, +1.4)

Stage 4

+0.6 (-0.3, +1.6)

Missing

+0.7 (-0.3, +1.8)

CD4 cell count at ART initiation (versus 250 cells/μL)

0.495

< 250 cells/μL

-0.1 (-1.4, +0.4)

Missing

-0.5 (-1.6, +0.5)

Regimen at ART initiation containing
NVP (versus EFV)

+1.0 (+0.3, +1.6)

0.006

d4T (versus AZT)

+0.9 (+0.3, +1.4)

0.003

Current age (per 10 years)

-0.1 (-0.4, +0.2)

0.479

Duration on ART (per year)

+0.1 (-0.1, +0.2)

0.400

CD4 cell count (versus 250 cells/μL)

NS

0.367

< 250 cells/μL

+0.6 (-0.3, +1.5)

Missing

-0.1 (-0.7, +0.6)

Current regimen containing
NVP (versus EFV)

+0.6 (-0.1, +1.3)

0.115

d4T (versus AZT)

+0.7 (-0.2, +1.5)

0.109

*Regression coefﬁcients and P-values calculated using linear regression with site as a ﬁxed effect.
Factors with negative coefﬁcients are associated with a reduced symptom burden; those with a positive coefﬁcient with an increased symptom burden.
d4T: stavudine; NVP: nevirapine; EFV: efavirenz; AZT: zidovudine; CI: conﬁdence interval.
doi:10.1371/journal.pone.0147309.t003

consistent data collection tool across 18 study sites in 3 countries in sub-Saharan Africa. This
paper builds on the study’s primary analysis that found that 3% of participants missed two or
more consecutive days of their ART in the past three months and that having greater numbers
of self-reported symptoms, (defined as more than the country-specific median), was significantly related to this measure of incomplete adherence.[9] In this secondary analysis we
focused on specific symptoms and their association with incomplete adherence, and on reasons
for ever missing ART.
This analysis found that about one third of participants (29%) reported ever missing ART.
Simply forgetting was cited as the most common reason for ever missing ART, a result which
concurs with findings from other studies.[19–21] Advances in mHealth technologies are
emerging as an option to address forgetting to take ART. For example, several studies have
found that patients who received text messages have better levels of ART adherence and clinical
indicators, such as lower viral loads and higher CD4 cell counts, compared to patients who did
not receive text messages.[22–24] However, in their network meta-analysis examining direct
and indirect evidence from randomized trials, Mills and colleagues found a large benefit for
weekly but not for daily SMS messages [25], emphasizing the need for tailored mHealth interventions.[26] Such findings support the inclusion of mobile phone text messaging in the package of adherence intervention tools, as recommended by the World Health Organization in
their latest guidelines, as well as the need for more research on how to optimize the use of text
messaging.[27] However, the potential of unwanted disclosure if the message is intercepted by
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Table 4. Analysis of individual symptoms with incomplete adherence as outcome (defined as missed ART for at least 48 consecutive hours during
the past 3 months) in multi-country (Tanzania, Uganda, and Zambia) adherence study, 2011.
Total
(n = 4425)
Reporting at least one symptom, n (%)

Incomplete adherence
(n = 141)

Crude Odds Ratio (OR)
(95% CI) *

Pvalue*

3907 (88.3)

136 (96.5)

2.95 (1.19–7.35)

0.007

Fatigue or loss of energy

1628 (36.8)

67 (47.5)

1.45 (1.01–2.06)

0.042

Pain, numbness, or tingling in the hands or feet

1560 (35.3)

57 (40.4)

1.11 (0.78–1.58)

0.562

Headache

1519 (34.3)

61 (43.3)

1.29 (0.91–1.83)

0.162

Felt sad, down or depressed

1309 (29.6)

63 (44.7)

1.49 (1.05–2.12)

0.029

Muscle aches or joint pains

1190 (26.9)

49 (34.8)

1.25 (0.87–1.80)

0.240

Fat deposits or weight gain

1147 (25.9)

37 (26.2)

0.99 (0.66–1.47)

0.950

Fevers, chills, or sweats

1135 (25.6)

52 (36.9)

1.67 (1.16–2.41)

0.007

Trouble remembering

1109 (25.1)

37 (26.2)

1.02 (0.69–1.52)

0.906

Cough or breathing difﬁculties

1026 (23.2)

51 (36.2)

1.80 (1.25–2.61)

0.002

Problems with having sex (such as loss of interest or a lack
of satisfaction)

1016 (23.0)

39 (27.7)

1.13 (0.76–1.66)

0.554

Weight loss or wasting

0.362

Symptom, n (%)

1010 (22.8)

39 (27.7)

1.20 (0.81–1.77)

Dizzy or lightheaded

999 (22.6)

45 (31.9)

1.42 (0.98–2.06)

0.071

Loss of appetite or change in taste of food

915 (20.7)

53 (37.6)

2.05 (1.43–2.95)

<0.001

Skin problems (rash, dryness, or itching)

843 (19.1)

48 (34.0)

1.95 (1.35–2.81)

<0.001

Difﬁculty falling or staying asleep

837 (18.9)

38 (27.0)

1.35 (0.91–1.99)

0.145

Felt nervous or anxious

812 (18.4)

38 (27.0)

1.27 (0.85–1.89)

0.256

Bloating, stomach pain, or gas

796 (18.0)

40 (28.4)

1.59 (1.08–2.34)

0.022

Nausea or vomiting

524 (11.8)

28 (19.9)

1.72 (1.11–2.67)

0.020

Diarrhoea or loose bowl movements

475 (10.7)

31 (22.0)

2.24 (1.47–3.43)

<0.001

179 (4.0)

6 (4.3)

1.01 (0.43–2.36)

0.975

Hair loss or hair change

*OR and P-value calculated using logistic regression with site as a ﬁxed effect.
OR: odds ratio; CI: conﬁdence interval.
doi:10.1371/journal.pone.0147309.t004

others, and the cost and sustainability of these mHealth interventions in the absence of external
funding, remain important issues.[28]
Having too much hunger because of ART or not having enough food was experienced by
about one-third of participants who reported ever missing ART. The mechanism of ARTrelated hunger is unclear, but the possibility of immunological phenomena may play a role.[29]
Food insecurity has been described as an important barrier to adherence and subsequent mortality in impoverished populations.[30–35] The integration of food supplementation into HIV
care programmes has been shown to improve adherence [36], and to have clinical and immunological benefits.[37] In order to address the underlying causes of food insecurity, organizations are looking for more sustainable long-term solutions to address this issue in the form of
livelihood programmes.[38] The lack of evidence and research on the integration of livelihood
programmes into HIV programmes [38] could be one of the reasons why these programmes
have not been more widely implemented. Further implementation research on how these programmes should be evaluated, and subsequent cost-effectiveness studies are needed.
Previous studies [19,20] have also found that being away from home for funerals and travelling (and running out of ART while travelling) were common reasons for missing ART. In our
study about 1% of all participants included, or 3% of participants ever missing ART, reported
this as a reason for missing ART. Currently cities and urban areas bear a major part of the
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global HIV burden—in sub-Saharan Africa, nearly half (45%) of people living with HIV reside
in urban areas.[39] Travelling and migration in and out of cities can be a challenge for retention in care and adherence but also an important factor linking different networks of HIV
transmission.[40] Interventions to provide patients with an adequate supply of ART are critical
to minimizing treatment interruptions during travel.
Lack of money for transport was mentioned by 12% of the participants who ever reported
missing ART and no transport to the pharmacy by 11%. This has also been cited in other studies as a risk factor for missed medical appointments at the health facility for follow-up and refill
because of competing demands between transport costs and other necessities such as food,
housing, and school fees.[30,41] Further decentralization of ART services, thereby bringing
ART services closer to the patients [42], and involving patients and their families as the model
of Community ART Groups (peer support) has the potential to further reduce transport costs
and thus minimize out-of-pocket payments.[43] In addition, reducing the frequency of followup visits for refills or for routine clinical monitoring may also contribute to reducing the cost
burden of transportation.
A large majority of patients (88%) in this study reported experiencing at least one symptom
from the HIV Symptom Index, and, not surprisingly, the odds of incomplete adherence
increased significantly with each additional symptom, as similarly described elsewhere.[44]
Patients who reported feeling sick and uncomfortable because of ART were about 4 times more
likely to have incomplete adherence, also confirming findings from other studies.[19,45] We
also found that women reported a significantly greater symptom burden (both more symptoms
and severity), as described elsewhere.[46]
Fatigue or loss of energy was the most reported symptom (37%), twice as much as reported
by Bhatt et. al in South Africa [19], but only attributed to ART by 19% of patients with fatigue.
On the other hand, pain, numbness, or tingling in the hands or feet was reported by 35% of
patients, and about one third of the patients who reported this symptom attributed it to ART.
This is comparable with findings from Thailand where 10% and 28% of probable and possible
HIV-associated neuropathy was reported.[47] Peripheral neuropathies are expected to be more
prevalent in settings where d4T is part of the first-line regimen.[48] Fortunately, the latest
WHO recommendations call for the phasing out of d4T-containing regimens and their
replacement by preferably tenofovir-containing regimens.[27] In this study, there was already
clear evidence of this change with the proportion of d4T-containing regimens decreasing from
37% at baseline to 18% at the time of the interview, and tenofovir-containing regimens increasing from 11% (at baseline) to 26% (at the time of the interview).
About one third of the patients (30%) reported feeling sad, down, or depressed in the previous four weeks based on the HIV Symptom Index. While we cannot conclude that a patient is
suffering from depression based on just one question, this number is surprisingly high and is
consistent with the report of moderate to severe depression symptom severity among people
living with HIV in sub-Saharan Africa. A systematic review, including 23 studies in sub-Saharan Africa, found prevalence estimates of 18% for major depression and 30% for depression
symptoms among HIV-positive patients on ART.[49] In their analysis, patients who reported
depression symptoms were 55% less likely to achieve good adherence compared to those not
reporting depression symptoms. Similarly, in our univariate analysis, participants who
reported feeling sad, down, or depressed were about 50% more likely to report incomplete
adherence. This finding supports the screening for depression among patients with HIV.[49]
However the region’s health system capacity to detect and treat depression is limited.[50] Dietary protein supplementation has been suggested as a specific strategy to further reduce depression in patients on ART, in settings with food insecurity.[29]
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Only one-third of participants reported ever missing ART, which may be low given that
other studies have found up to 20% of participants missed taking their ART over just the past
week alone.[51] It is well-established that self-report surveys tend to overestimate actual adherence.[52] However, this overestimate may also introduce a bias by not capturing the reasons
for missed ART among both people willing to disclose, as well as among people unwilling to
disclose incomplete adherence behaviors.
This study was conducted in 2011 before the WHO guidelines to replace d4T-containing
regiments with tenofovir-containing regiments were introduced. [27] As such the factors
related to missing ART may differ among patients on tenofovir-containing regimens.
We found some variability in the proportion of symptoms attributed to ART by patients:
symptoms of peripheral neuropathy, troubles with remembering, nausea and vomiting, skin
problems and problems with having sex were mostly attributed to ART. This could potentially
lead to some bias with less adherent individuals more likely to report symptoms and attribute
them to their ART. The cross-sectional design of the study limits the causal inference of
whether it is incomplete adherence that leads to symptoms or whether it is the symptoms that
are leading to incomplete adherence. Another limitation of the study is the difficulty in attributing symptoms to ART; some of these symptoms may also arise from the HIV infection itself,
or arise from co- morbidities frequently associated with HIV infection (diabetes, hepatitis C
infection).[53] We were also unable to assess whether ART clients who declined to participate
differed from those participating in the study.

Conclusions
Symptoms were a common reason for missing ART, together with simply forgetting and food
insecurity. Women and participants taking ART regimens containing d4T at initiation experienced greater symptom burden. A combination of ART regimens with fewer side effects, use of
mobile phone text messaging, and integration of food supplementation and livelihood programmes into HIV programmes, have the potential to decrease missed doses of ART and
hence to improve adherence and the outcomes of ART programmes.
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